146 related articles for article (PubMed ID: 37496404)
1. Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution.
Fontanals S; Esteve A; González A; Ibáñez C; Martínez J; Mesía R; Clopés A
Cancer Med; 2023 Aug; 12(16):17112-17125. PubMed ID: 37496404
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience.
Fontanals S; Esteve A; González A; Ibáñez C; Mesía R; Clopés A
Pharmacol Res Perspect; 2024 Feb; 12(1):e1167. PubMed ID: 38193611
[TBL] [Abstract][Full Text] [Related]
3. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
4. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
5. Off-label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center.
Cenna R; Basiricò M; Berchialla P; Bertorello N; Cagnazzo C; Ceolin V; De Luna E; Nolis C; Resente F; Fagioli F
Pediatr Blood Cancer; 2023 Mar; 70(3):e30148. PubMed ID: 36583462
[TBL] [Abstract][Full Text] [Related]
6. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
7. Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
Käsmann L; Taugner J; Eze C; Roengvoraphoj O; Dantes M; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
Anticancer Res; 2019 Sep; 39(9):5077-5081. PubMed ID: 31519618
[TBL] [Abstract][Full Text] [Related]
8. Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India.
M SG; Mohapatra PR; Bhuniya S; Das Majumdar SK; Mishra P; Panigrahi MK; Bal SK; Datta A; Venkatachalam P; Chatterjee D
Cureus; 2022 Oct; 14(10):e30589. PubMed ID: 36420233
[TBL] [Abstract][Full Text] [Related]
9. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.
Joris S; Pieters T; Sibille A; Bustin F; Jacqmin L; Kalantari HR; Surmont V; Goeminne JC; Clinckart F; Pat K; Demey W; Deschepper K; Lambrechts M; Holbrechts S; Schallier D; Decoster L
J Geriatr Oncol; 2020 Jun; 11(5):796-801. PubMed ID: 31791821
[TBL] [Abstract][Full Text] [Related]
12. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
[TBL] [Abstract][Full Text] [Related]
15. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
Takahashi M; Takahashi M; Komine K; Yamada H; Kasahara Y; Chikamatsu S; Okita A; Ito S; Ouchi K; Okada Y; Imai H; Saijo K; Shirota H; Takahashi S; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(6):e0179694. PubMed ID: 28640844
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
[TBL] [Abstract][Full Text] [Related]
17. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
18. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Felip E; Ardizzoni A; Ciuleanu T; Cobo M; Laktionov K; Szilasi M; Califano R; Carcereny E; Griffiths R; Paz-Ares L; Duchnowska R; Garcia MA; Isla D; Jassem J; Appel W; Milanowski J; Van Meerbeeck JP; Wolf J; Li A; Acevedo A; Popat S
Eur J Cancer; 2020 Mar; 127():160-172. PubMed ID: 32028209
[TBL] [Abstract][Full Text] [Related]
19. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.
Berlanga P; Ndounga-Diakou LA; Aerts I; Corradini N; Ducassou S; Strullu M; de Carli E; André N; Entz-Werle N; Raimbault S; Roumy M; Renouard M; Gueguen G; Plantaz D; Reguerre Y; Cleirec M; Petit A; Puiseux C; Andry L; Klein S; Bodet D; Kanold J; Briandet C; Halfon-Domenech C; Nelken B; Piguet C; Saumet L; Chastagner P; Benadiba J; Millot F; Pluchart C; Schneider P; Thouvenin S; Gambart M; Serre J; Abbou S; Leruste A; Cayzac H; Gandemer V; Laghouati S; Vassal G
JAMA Netw Open; 2023 Jul; 6(7):e2321568. PubMed ID: 37399010
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
